ReviewActa pharmaceutica Sinica. B2021
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Erratum issuedOpen access · diamondAbstract readReview
In one paragraph
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 133 citations in OpenAlex.
- Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives.RSC advances · 2026Article
- Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.Clinical journal of gastroenterology · 2026Article
- Characteristics of fusion genes in breast cancer.Cancer cell international · 2026Review
- Alterations of actin in aging.Journal of cell science · 2026Review
- MET-mediated phosphorylation of YANK2 at Y282 inhibits NEDD4L-dependent SUMOylation and degradation, promoting chemoresistance in glioblastoma.Molecular biomedicine · 2026Article
- Structural insights into the specificity of adaptor proteins Dok5 and Dok6 Docking to Trk receptors.Cell communication and signaling : CCS · 2026Article
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Identification and Functional Characterization of Novel and Recurrent NTRK1 Variants in Chinese Families With Congenital Insensitivity to Pain With Anhidrosis: A Combined Clinical, Genetic, and Functional Study.European journal of neurology · 2026Article
- Improvement of prognosis among patients with lung adenocarcinoma through precision therapy: analysis based on The Cancer Genome Atlas.Translational cancer research · 2026Article
- Entrectinib attenuates LPS-induced neuroinflammation by inhibiting JNK, p38, and AKT pathways and ameliorates cognitive impairment.Archives of pharmacal research · 2026Article
- TrkA activation sustains chemotherapy resistance in chemotolerant medulloblastoma cells.Acta neuropathologica communications · 2026Article
- Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.Nature communications · 2026Article
- The influence of neuro-tumor interactions on tumorigenesis and therapeutic response.Experimental hematology & oncology · 2026Review
- A Comprehensive Review of Designing and Synthetic Aspects of Pyrazolopyrimidine Derivatives as Anticancer Agents.Mini reviews in medicinal chemistry · 2026Review
- Adult Low-Grade Glioma WithCase reports in pathology · 2026Article
- Beyond Glucose and Lipids: The Pivotal Role of Amino Acid Reprogramming in Shaping the Tumor Microenvironment and Guiding the Development of Novel Therapeutics.International journal of medical sciences · 2026Review
- Mechanosensitive snoRNA-like circular RNA sno-circCNOT1 drives endothelial dysfunction and atherosclerosis.Theranostics · 2026Article
- Decoding autophagy in neuro-tumor crosstalk: from underlying mechanisms to translational opportunities.Theranostics · 2026Review
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Successful treatment of pediatric scalp mesenchymal tumor with NTRK rearrangement: a case report.Translational pediatrics · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Tingting JiangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Guan WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Yao LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Lu FengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Meng WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Jie LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Yi ChenState Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
Liang OuyangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
State Key Laboratory of BiotherapySichuan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (
Indexed as
AFAP1, actin filament-associated protein 1AML, acute myeloid leukemiaARHGEF2, Rho/Rac guanine nucleotide exchange factor 2BCAN, brevicanBDNF, brain-derived neurotrophic factorBTBD1, BTB (POZ) domain containing 1CDK-2, cyclin-dependent kinase 2CRC, colorectal cancerCR, complete responseCTCs, sequencing of circulating tumor cellsDFG, Asp-Phe-GlyDOR, durable objective responsesETV6, ETS translocation variant 6EWG, electron-withdrawing groupFDA, U.S. Food and Drug AdministrationFISH, fluorescence in situ hybridizationGBM, glioblastoma multiformeHNSCC, head and neck squamous cell carcinomaHTS, high-throughput screeningICC, intrahepatic cholangiocarcinomaIG-C2, Ig-like C2 type ILMNA, lamin A/CMASC, mammary analogue secretory carcinomaMPRIP, myosin phosphatase Rho interacting proteinNACC2, NACC family member 2NCCN, National Comprehensive Cancer NetworkNeurotrophic receptor tyrosine kinase fusionsNFASC, neurofascinNGF, nerve growth factorNGS, next-generation sequencing of tumor tissueNSCLC, non-small cell lung cancerNT3, neurotrophin-3NTRK fusion cancerNTRK, neurotrophic receptor tyrosine kinaseOAK, osteoarthritis of the kneeORR, overall response ratePAN3, poly(A) nuclease 3PPL, periplakinPROTAC proteolysis targeting chimera, QKIquaking I protein, RABGAP1LRABGTPase activating protein 1-like, RFWD2ring finger and WD repeat domain 2, E3 ubiquitin protein ligaseRTK, receptor tyrosine kinaseSAR, structure–activity relationshipSBC, secretory breast carcinomaSCYL3, SCY1 like pseudokinase 3Small-molecule inhibitorSQSTM1, sequestosome 1TFG, TRK-fused geneTP53, tumor protein P53TPM3, tropomyosin 3TPR, translocated promoter regionTRIM24, tripartite motif containing 24TRK, tropomyosin receptor kinaseTropomyosin receptor kinaseVCL, vinculinVEGFR2, vascular endothelial growth factor receptor 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.